SUMMARY The immediate haemodynamic dose response effects of beta blockade (propranolol: 2 to 16 mg) were compared with those of combined alpha beta blockade (labetalol: 10 to 80 mg) in a randomised study of 20 patients with stable angina pectoris. After control measurements, the circulatory changes induced by four logarithmically cumulative intravenous boluses of each drug in equivalent beta blocking doses were evaluated at rest, after which comparison of the effects of the maximum cumulative dose of each was undertaken during a four minute period of supine bicycle exercise.
Propranolol, at rest, induced significant dose related reductions in heart rate and cardiac output, with reciprocal increases in the systemic vascular resistance and pulmonary artery occluded pressure; systemic arterial pressure was unchanged. Labetalol was followed by significant dose related decreases in systemic blood pressure and vascular resistance associated with a significant increase in cardiac output; heart rate and pulmonary artery occluded pressure were unchanged. The slope of the left ventricular pumping function curve relating output to filling pressure from rest to exercise was significantly depressed by propranolol but unchanged after labetalol.
The less deleterious effects on left ventricular haemodynamic performance after alpha beta blockade in contrast to beta blockade alone in ischaemic heart disease may be attributable to the concomitant reduction in left ventricular afterload associated with the alpha blocking activity of labetalol.
A major consequence of coronary heart disease is a reduction in left ventricular haemodynamic performance; the increased workload of exercise frequently results in its acute but reversible pumping failure. '-3 The symptomatic effectiveness of beta blocking drugs is a result of the reduction in heart rate and myocardial contractility, two of the major determinants of left ventricular oxygen consumption.4 5 These haemodynamic advantages, however, may be offset to a varying extent by the accompanying increase in enddiastolic pressure6 7 and volume8 9 which result from blockade of the inotropic beta adrenoceptors in the left ventricle. Increase in end-diastolic pressure can be expected to increase subendocardial coronary resistance, and the increase in end-diastolic volume to offset some of the saving in left ventricular oxygen consumption achieved by the reduction in heart rate and myocardial contractility.
Accepted for publication 22 The plasma concentration of both drugs was measured using high performance liquid chromatography with fluorimetric detection. The assay for propranolol was specific for unchanged drug, linear over the range 10 to 1000 ng/ml (coefficient of variation 7 2%) and with a lower limit of sensitivity of 2 5 ng/ ml.'6 The assay for labetalol was specific, linear over the plasma concentration range 50 to 2500 ng/ml (coefficient of variation: 5%) and with a lower limit of sensitivity of 2 ng/ml. The probability of statistical significance of differences between control and post-drug data was Silke, Nelson, Ahuja, Taylor tested by analysis of variance of repeated measurements. 17 Tukey's multiple comparison procedure'8 was used to generate the single value for two confidence levels, thus allowing the significance of differences between the incremental effects of each drug on each haemodynamic variable, both at rest and during exercise, to be ascertained.
Results
The study was accomplished without untoward incident in any patient. Eight of the 10 patients given propranolol and seven of those given labetalol volunteered the information that the severity of the exercise-induced anginal pain was less after the drug than in the control study.
HOMOGENEITY OF GROUPS (Table 1) The randomisation achieved comparable distribution between the groups in terms of the extent of the angiographic coronary artery disease. The duration of symptoms was marginally longer in the labetalol group but their overall left ventricular performance, in terms of the relation between filling pressure and output during exercise was substantially more depressed than that of patients randomised to propranolol.
MEASUREMENTS IN CONTROL STUDIES AT REST
In the control study the variability of the haemodynamic variables at rest was small in both groups and none showed any significant trend to change over the 16 minute period of measurement. For the purposes of analysis the measurements for each group from the four control periods were therefore averaged. In the resting control period the average coefficients of variation (range) for the 20 patients were: systolic blood pressure 1-7% (0 3 to 2-8%), diastolic blood pressure 2% (1-2 to 4 0%), heart rate 3-3% (0 to 6 2%), cardiac output 3-3% (1 7 to 5 9%), and pulmonary artery occluded pressure 8% (3 5 to 12-3%).
HAEMODYNAMIC EFFECTS OF PROPRANOLOL ( Fig. 2 and 3 ; Tables 2 and 3 (Fig. 3) The effects of propranolol and labetalol on the relation between the cardiac output and pulmonary artery occluded pressure at rest and during exercise showed distinct differences. Propranolol was followed by a significant shift to the right in the rest-to-exercise relation between left ventricular filling pressure and its pumped output (p<OO1); increase in filling pressure and reduction in output both contributed to this changed relation. Labetalol induced no substantial Hoemodynamics ofpropranolol and labetalol in angina change in the relation between these two variables despite the initially greater overall depression of left ventricular function.
PLASMA CONCENTRATIONS
The plasma concentrations (mean±SEM) after the four cumulative intravenous boluses of propranolol were 77±30, 92±20, 191±55, and 454±118 ng/ml.
The respective mean plasma concentrations oflabetalol were 319±07, 420±142, 826±249, and 1125±209 ng/ ml. The plasma concentrations showed significant loglinear increases after each drug (propranolol r=0-78, p<0 001; labetalol r=0-82, p<0 001). pressure28) and also the result of direct blockade of vasodilator beta-2 adrenoceptors in the peripheral arteriolar resistance vessels. In contrast, labetalol resulted in a dose related increase in the pumped output of the left ventricle at the same filling pressure and heart rate, presumably because of the reduction in left ventricular afterload consequent upon its direct vasodilator activity. During exercise the separation of the haemodynamic effects of the two drugs was even greater, despite the greater initial impairment of left ventricular performance in the labetalol group. In the latter group the relation between the filling pressure of the left ventricle and its output was largely unchanged by combined alpha and beta blockade whereas this haemodynamic relation was significantly depressed after propranolol. Again, presumably as a reflection of further depression of left ventricular function, the systemic vascular resistance during exercise was increased after propranolol but unchanged after labetalol. Thus, the contrasting pharmacodynamic effects of the two drugs in these patients with coronary heart disease were largely explicable by the possession of vasodilator alpha adrenoceptor blocking activity by labetalol.
These results with propranolol are in accord with previous single dose2930 and multiple dose response studies3' in patients with coronary heart disease. The circulatory effects of labetalol in normal volunteers, '5 and in patients with essential hypertension,32 were similar to those we recorded in our patients. The only other haemodynamic evaluation of labetalol in normotensive patients with angina pectoris was a single dose study carried out at rest.33 Ten minutes after an average intravenous bolus of 1-5 mg/kg systemic blood pressure and vascular resistance were reduced to a similar order to that after the maximum cumulative dose in the present study, cardiac output was unchanged and there was a small insignificant fall in pulmonary wedge pressure. These .results are compatible with ours and highlight the important influence of dose response studies and physiological exercise in analysing the haemodynamic effects of a drug.
How far these results can be extrapolated to the medical treatment of patients with angina cannot be decided from these studies. Labetalol, however, has been shown to be symptomatically effective, both in normotensive (unpublished observations) and hypertensive patients with angina pectoris.34 35 Our results also suggest that the drug may be particularly useful in the treatment of angina patients with severe left ventricular dysfunction or in those with an inadequate response to beta blocking drugs alone.
It is important, however, to emphasise that these observations, however haemodynamically instructive, were based on the results of intravenous studies, and can be extended to the wider therapeutic field only with caution. Definitive studies of the clinical efficacy of combined alpha and beta blockade during long term treatment of patients with angina pectoris and those with asymptomatic coronary heart disease undergoing secondary preventive treatment are necessary before the true therapeutic value of this new pharmacological approach can be decided. Our results, however, furnish an optimistic basis for the institution of such studies in patients with stable coronary heart disease. 
